8-K: Iterum Therapeutics Receives FDA Approval for ORLYNVAH, a Novel Oral Antibiotic for Uncomplicated UTIs

Iterum Therapeutics has secured FDA approval for ORLYNVAH, a new oral antibiotic for treating uncomplicated urinary tract infections in adult women with limited treatment options.

Summary

• Iterum Therapeutics has received FDA approval for ORLYNVAH, an oral antibiotic for treating uncomplicated urinary tract infections (uUTIs) in adult women.
• ORLYNVAH is indicated for uUTIs caused by Escherichia coli, Klebsiella pneumoniae, or Proteus mirabilis when other oral options are limited.
• This is the first FDA-approved product for Iterum and the first oral penem antibiotic approved in the U.S.
• The approval was based on two Phase 3 clinical trials, SURE 1 and REASSURE, which demonstrated the drug's efficacy and safety.
• SURE 1 showed superiority to ciprofloxacin in fluoroquinolone-resistant infections, while REASSURE showed non-inferiority and statistical superiority to Augmentin in the Augmentin-susceptible population.
• The company estimates that approximately 1% of the 40 million annual uUTI prescriptions in the U.S. are for infections resistant to commonly available oral antibiotics.
• Iterum plans to renew efforts to achieve a strategic transaction for ORLYNVAH, aiming to maximize value for stakeholders.
• If a strategic transaction is not achieved, the company may seek a commercial partner or commercialize the drug directly with a targeted sales force.

Sentiment

Score: 8

Explanation: The document is highly positive due to the FDA approval of ORLYNVAH, a significant milestone for the company. The company is actively seeking a strategic transaction, which could lead to further value creation. However, there are risks associated with commercialization and the need for additional capital.

Positives

• ORLYNVAH is the first oral penem antibiotic approved in the U.S., offering a new treatment option for uUTIs.
• The drug has shown superiority to ciprofloxacin in fluoroquinolone-resistant infections and non-inferiority and statistical superiority to Augmentin in the Augmentin-susceptible population.
• The FDA approval provides a clear label for the drug, which may facilitate a strategic transaction.
• The drug addresses a significant unmet need, as approximately 1% of uUTI prescriptions are for infections resistant to common oral antibiotics.
• The company has a clear path forward, either through a strategic transaction or direct commercialization.

Negatives

• The company's future plans are contingent on securing a strategic transaction or raising sufficient capital.
• There is no guarantee that a strategic transaction will be completed.
• The company may need to build a sales force if a strategic transaction is not achieved.
• The drug is not indicated for complicated UTIs or as a step-down treatment after intravenous antibacterial treatment.
• There are potential side effects, including diarrhea, nausea, and hypersensitivity reactions.

Risks

• The success of ORLYNVAH depends on the company's ability to secure a strategic transaction or raise sufficient capital.
• There is a risk that the strategic review process may not result in a transaction.
• The company faces risks related to commercialization, including building a sales force and achieving market acceptance.
• There are risks associated with regulatory changes and the actions of third-party clinical research organizations, suppliers, and manufacturers.
• The company's ability to maintain its listing on the Nasdaq Capital Market is also a risk.

Future Outlook

The company plans to pursue a strategic transaction for ORLYNVAH to maximize value. If unsuccessful, they may seek a commercial partner or commercialize the drug directly. The company's future is dependent on securing a strategic transaction or raising sufficient capital.

Management Comments

• 'ORLYNVAH offers new hope for patients suffering from difficult-to-treat uUTIs,' said Corey Fishman, Iterum's Chief Executive Officer.
• 'The introduction of novel products, like ORLYNVAH, is an important way to combat antimicrobial resistance to other approved oral agents and offers a potential solution to patients and physicians,' said Corey Fishman.
• 'With FDA approval and a clear label, we will renew our efforts to achieve a strategic transaction involving ORLYNVAH with the goal of maximizing value for our stakeholders,' said Corey Fishman.
• 'Based on the totality of clinical data generated, ORLYNVAH has the potential to be an important treatment alternative for use in the community,' said Marjorie Golden, MD, FIDSA.

Industry Context

The approval of ORLYNVAH addresses the growing concern of antibiotic resistance and the need for new treatment options for urinary tract infections. It is the second FDA-approved treatment for uUTIs in the past two decades, highlighting the limited innovation in this area. The drug's unique mechanism of action as an oral penem antibiotic positions it as a potential alternative to existing treatments.

Comparison to Industry Standards

• ORLYNVAH is the first oral penem antibiotic approved in the U.S., setting it apart from other oral antibiotics used for uUTIs, such as fluoroquinolones (e.g., ciprofloxacin) and beta-lactams (e.g., Augmentin).
• The clinical trials, SURE 1 and REASSURE, compared ORLYNVAH to ciprofloxacin and Augmentin, respectively, demonstrating its superiority in certain cases and non-inferiority in others.
• The company estimates that 1% of uUTI infections are resistant to commonly available oral antibiotics, highlighting the need for new options like ORLYNVAH.
• Companies like Melinta Therapeutics (acquired by Innoviva) and Nabriva Therapeutics have also focused on developing new antibiotics, but ORLYNVAH's oral penem formulation is a unique offering.
• The market for uUTI treatments is large, with approximately 40 million prescriptions annually in the U.S., indicating a significant commercial opportunity for ORLYNVAH.

Stakeholder Impact

• Shareholders may benefit from the FDA approval and potential strategic transaction.
• Patients with uUTIs may have a new treatment option.
• Employees may have increased job security due to the company's progress.
• The company's success may impact suppliers and other partners.

Next Steps

• The company will host a conference call on October 28, 2024, to discuss the FDA approval.
• Iterum will renew its efforts to achieve a strategic transaction involving ORLYNVAH.
• If a strategic transaction is not achieved, the company may seek a commercial partner or commercialize the drug directly.

Key Dates

Keywords

ORLYNVAH, sulopenem, uUTI, antibiotic, FDA approval, Iterum Therapeutics, urinary tract infection, antimicrobial resistance, strategic transaction, oral penem